Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 923Lung Neoplasms 626Small Cell Lung Carcinoma 172Colorectal Neoplasms 136Melanoma 110Breast Neoplasms 108Neoplasms 98Ovarian Neoplasms 94Neoplasm Metastasis 91Pancreatic Neoplasms 77Squamous Cell Carcinoma of Head and Neck 70Stomach Neoplasms 60Carcinoma, Renal Cell 58Head and Neck Neoplasms 57Triple Negative Breast Neoplasms 51Esophageal Neoplasms 51Endometrial Neoplasms 51Prostatic Neoplasms 47Uterine Cervical Neoplasms 44Colonic Neoplasms 43Urinary Bladder Neoplasms 41Mesothelioma 41Mesothelioma, Malignant 38Carcinoma, Hepatocellular 38Brain Neoplasms 34Sarcoma 30Carcinoma, Transitional Cell 29Adenocarcinoma of Lung 29Lung Diseases 26Disease 26

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Thoracic × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡